Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!
Behind the scenes of 3P innovation's Customer Care team

Behind the scenes of 3P innovation's Customer Care team

Picture of Georgia Lewis-Marston Georgia Lewis-Marston: 17 October 2025

This week, I had the chance to sit down with Paul Beard, Operations Director at 3P innovation, to explore what truly distinguishes our Customer Care...

Read More
Filling syringes with spray-dried powders - the how, the why and the benefits.

Filling syringes with spray-dried powders - the how, the why and the benefits.

David Phasey: 15 October 2025

For many therapy developers, the challenge doesn’t start in manufacturing, it begins much earlier in formulation. Once a promising therapy has...

Read More
What does Annex 1 mean for cryovial filling? Insights from 3P innovation.

What does Annex 1 mean for cryovial filling? Insights from 3P innovation.

Charles Pilato: 6 October 2025

The revision of EU GMP Annex 1 has redefined expectations for sterile manufacturing across the life sciences sector and nowhere is this felt more...

Read More